MedTrace Logo

Oral Dietary Fucoxanthin Rich Supplement for Liver Health

NCT03625284 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-08-14

No results posted yet for this study

Summary

Blind, placebo-controlled study testing the hypothesis that oral dietary supplement rich with fucoxanthin will decrease biochemical clinical markers related to liver health.

Conditions

  • Non Alcoholic Fatty Liver

Interventions

DIETARY_SUPPLEMENT

Placebo

Edible oil

DIETARY_SUPPLEMENT

FucoVital

Microalgae oil extract

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    collaborator OTHER_GOV

  • Algatechnologies Ltd.

    lead INDUSTRY

Principal Investigators

  • Haim Shirin, Prof. · Director Institute of Gastroenterolgy, Liver Diseases and Nutrition

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2019-09-10
Completion
2019-12-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03625284 on ClinicalTrials.gov